Skip to main content
. 2021 Jul 2;10(7):1669. doi: 10.3390/cells10071669

Figure 4.

Figure 4

High expression of YTHDF1 in the KRAS/TP53-mut group was correlated with cyclin B1, unfavorable clinical stage, and tumor size. (a) Representative images of IHC staining for YTHDF1 and cyclin B1 expressions in tumor sections from human lung cancer specimens of the four different mutation groups. (b,c) Comparison of the IHC staining score of YTHDF1 (b) and cyclin B1 (c) in wildtype (n = 11), KRAS-mut (n = 18), TP53-mut (n = 18), and KRAS/TP53-mut (n = 23) groups. (d) Correlation analysis of the YTHDF1 H-score and cyclin B1 H-score (n = 70). (e) Correlation heatmap of the clinical characteristics in 70 cases of LUAD patients. p < 0.01; *** p < 0.001.